Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, William L. Dahut, Anna Couvillon et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 312
Clinical Evaluation and Biomarker Profiling of Hsp90 InhibitorsAkira Yuno, Jane B. Trepel, Min-Jung Lee et al.|Methods in molecular biology|2017Cited by 122
Identification of immunogenic LY6K long peptide encompassing both CD4<sup>+</sup>and CD8<sup>+</sup>T-cell epitopes and eliciting CD4<sup>+</sup>T-cell immunity in patients with malignant diseaseYusuke Tomita, Yasuharu Nishimura, Akira Yuno et al.|OncoImmunology|2014Cited by 17